Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide vs Furosemide for Insulin Resistance in Heart Failure
NCT00372762Phase 3Withdrawn
- Start
- Jan 2011
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bumetanide in heart failure (HF) (2 arms). Primary endpoint: Insulin resistance by FSIGT MINMOD at 3 months. Planned start Jan 2011; status: withdrawn.
02
Drugs
bumetanide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00372762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00372762.